BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, March 1, 2026
Home » Topics » Financings

Financings
Financings RSS Feed RSS

Financings for Feb. 10, 2020

Feb. 10, 2020
Biopharmas raising money in public or private financings, including: Adaptimmune, Assertio, Collegium, Mereo.
Read More

Financings for Feb. 7, 2020

Feb. 7, 2020
Med-tech firms raising money in public or private financings, including: Aurora Spine.
Read More
2-7-Sensome-Clotild.png

Sensome raises $9M series B funding round for Clotild guidewire

Feb. 7, 2020
By Bernard Banga
PARIS – Sensome SAS, of Palaiseau, France, has closed a second funding round, of $9 million, with its original French investors (Kurma Partners SA, Invest Partners SA, BNP Paribas Développement SA and the Paris-Saclay Seed Fund), now joined by the Japanese-based Asahi Intecc Co. Ltd.
Read More

Financings for Feb. 7, 2020

Feb. 7, 2020
Biopharmas raising money in public or private financings, including: Adma, AGTC, Dare, Inventiva, Miragen, Orphazyme, Phio, Rapt, Salarius, Tonix.
Read More

Financings for Feb. 6, 2020

Feb. 6, 2020
Med-tech firms raising money in public or private financings, including: Connectyx Technologies, Lunaphore Technologies, Pentixapharm, Rewalk Robotics.
Read More
European Union flag, coins

Azafaros closes $28M series A for dual-acting enzyme inhibitors in lysosomal storage disease

Feb. 6, 2020
By Cormac Sheridan
DUBLIN – Azafaros BV raised €25 million (US$27.5 million) to develop orally available azasugar drugs with potential application to multiple lysosomal storage diseases.
Read More

Financings for Feb. 6, 2020

Feb. 6, 2020
Biopharmas raising money in public or private financings, including: AGTC, Arch Biopartners, Atyr, Beam, Chi-Med, Cortexyme, Kineticos, Moleculin, Pentixapharm, Sonoma, Valo.
Read More
2-5-Lumos-Febridx.png

Lumos Diagnostics scoops up $15M in series A to back Febridx test

Feb. 5, 2020
By Liz Hollis
With an eye toward expanding the reach of its Febridx rapid point-of-care (POC) test, Lumos Diagnostics Holdings Pty. Ltd. has seen the closing of a $15 million series A round from Australia’s Planet Innovation. The funds will back a U.S. FDA pivotal clinical trial, as well as additional development and manufacturing resources for the company’s expanding full-service POC business.
Read More

Maat Pharma edges toward FMT data readout with $20M series B round

Feb. 5, 2020
By Cormac Sheridan
DUBLIN – Maat Pharma SA closed an €18 million (US$19.9 million) series B round to continue development of its standardized, off-the-shelf fecal microbiota transplant (FMT) therapy, MaaT-013.
Read More

Financings for Feb. 5, 2020

Feb. 5, 2020
Med-tech firms raising money in public or private financings, including: Integra Lifesciences Holdings, Itamar Medical, Jenavalve Technology, Verana Health.
Read More
Previous 1 2 … 607 608 609 610 611 612 613 614 615 … 655 656 Next

Popular Stories

  • Today's news in brief

    BioWorld
  • Illustration of SCAN in Parkinson’s vs healthy subcortex

    SCAN is core circuit affected in Parkinson’s disease

    BioWorld
    Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
  • 3D rendering of skin cells and elastin with collagen layer

    First-in-class pan-inflammasome blocker for hidradenitis suppurativa

    BioWorld Science
    Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
  • Illustration of cancer cell in crosshairs being destroyed

    RX-10616 improves radiotherapy efficacy in HNSCC

    BioWorld Science
    Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
  • Brain and virus with chromosome

    CROI 2026: Neurodegeneration, the challenge of aging with HIV

    BioWorld
    Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing